Drug Profile
Tuvatexib - VidacPharma
Alternative Names: VDA-1102Latest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator VidacPharma
- Class Antineoplastics; Skin disorder therapies; Small molecules
- Mechanism of Action Hexokinase inhibitors; Keratinocyte modulators; Voltage-dependent anion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Actinic keratosis; Cutaneous T-cell lymphoma
- Preclinical Solid tumours
- No development reported Squamous cell cancer
Most Recent Events
- 12 Mar 2024 Vidac Pharma received approval from the Helsinki Committee of the Beilinson Hospital in Israel to proceed with the second stage of a Phase IIa trial of VDA-1102 in mycosis fungoides
- 12 Mar 2024 Vidac Pharma plans a phase IIa trial for Mycosis Fungoides
- 29 Jan 2024 Preclinical trials in Solid tumours in Israel (PO) (VidacPharma pipeline, January 2024)